MM-093

Generic Name
MM-093
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children. Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. The presence of hAFP in the pregnant mother’s blood has long been associated with remission of many autoimmune diseases, including rheumatoid arthritis, psoriasis and multiple sclerosis, during the third trimester of pregnancy. Current studies are assessing MM-093’s potential to improve the treatment of autoimmune disease.

Indication

Investigated for use/treatment in autoimmune diseases, psoriasis and psoriatic disorders, and rheumatoid arthritis.

Associated Conditions
-
Associated Therapies
-

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-04-09
Last Posted Date
2008-03-27
Lead Sponsor
Merrimack Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT00458146
Locations
🇺🇸

East Valley Rheumatology & Osteoporosis, Gilbert, Arizona, United States

🇺🇸

Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States

🇺🇸

Montgomery Rheumatology Associates, Montgomery, Alabama, United States

and more 17 locations

Phase 2 Study of MM-093 to Treat Patients With Uveitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-03-08
Last Posted Date
2008-12-18
Lead Sponsor
Merrimack Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT00444743
Locations
🇺🇸

MERSI, Cambridge, Massachusetts, United States

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
First Posted Date
2005-09-07
Last Posted Date
2007-02-23
Lead Sponsor
Merrimack Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT00147329
Locations
🇺🇸

U. of Utah School of Medicine- Department of Dermatology, Salt Lake City, Utah, United States

🇺🇸

Texas Dermatology Research Institute, Dallas, Texas, United States

Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)

Phase 2
Completed
Conditions
First Posted Date
2005-03-21
Last Posted Date
2008-07-11
Lead Sponsor
Merrimack Pharmaceuticals
Target Recruit Count
260
Registration Number
NCT00105976
Locations
🇺🇸

New England Research Associates, Bridgeport, Connecticut, United States

🇺🇸

Rheumatology Associates, PC, Indianapolis, Indiana, United States

🇺🇸

Houston Institute for Clinical Research, Houston, Texas, United States

and more 35 locations
© Copyright 2024. All Rights Reserved by MedPath